Redefining therapeutic success in HIV patients: an expert viewAntonio Antela, Santos Jesús, Belén de la Fuente García et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 30
Very low level viraemia and risk of virological failure in treated <scp>HIV</scp>‐1‐infected patientsRamón Teira, Francesc Vidal, Pepa Muñoz-Sánchez et al.|HIV Medicine|2016Cited by 23
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish CohortRamón Teira, Adrián Curran, Helena Díaz-Cuervo et al.|Infectious Diseases and Therapy|2022Cited by 6
Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive StudyDaniel Podzamczer, The TORAL Study Group, Estebán Martínez et al.|Current HIV Research|2012Cited by 3
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohortRamón Teira, Núria Espinosa, Helena Díaz-Cuervo et al.|HIV Research & Clinical Practice|2021Cited by 3